Cargando…

Tumor growth effects of rapamycin on human biliary tract cancer cells

BACKGROUND: Liver transplantation is an important treatment option for patients with liver-originated tumors including biliary tract carcinomas (BTCs). Post-transplant tumor recurrence remains a limiting factor for long-term survival. The mammalian target of rapamycin-targeting immunosuppressive dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Heuer, Matthias, Dreger, Nici M, Cicinnati, Vito R, Fingas, Christian, Juntermanns, Benjamin, Paul, Andreas, Kaiser, Gernot M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462134/
https://www.ncbi.nlm.nih.gov/pubmed/22721369
http://dx.doi.org/10.1186/2047-783X-17-20
Descripción
Sumario:BACKGROUND: Liver transplantation is an important treatment option for patients with liver-originated tumors including biliary tract carcinomas (BTCs). Post-transplant tumor recurrence remains a limiting factor for long-term survival. The mammalian target of rapamycin-targeting immunosuppressive drug rapamycin could be helpful in lowering BTC recurrence rates. Therein, we investigated the antiproliferative effect of rapamycin on BTC cells and compared it with standard immunosuppressants. METHODS: We investigated two human BTC cell lines. We performed cell cycle and proliferation analyses after treatment with different doses of rapamycin and the standard immunosuppressants, cyclosporine A and tacrolimus. RESULTS: Rapamycin inhibited the growth of two BTC cell lines in vitro. By contrast, an increase in cell growth was observed among the cells treated with the standard immunosuppressants. CONCLUSIONS: These results support the hypothesis that rapamycin inhibits BTC cell proliferation and thus might be the preferred immunosuppressant for patients after a liver transplantation because of BTC.